scholarly journals Current Status of Nonculture Methods for Diagnosis of Invasive Fungal Infections

2002 ◽  
Vol 15 (3) ◽  
pp. 465-484 ◽  
Author(s):  
Siew Fah Yeo ◽  
Brian Wong

SUMMARY The incidence of invasive fungal infections has increased dramatically in recent decades, especially among immunocompromised patients. However, the diagnosis of these infections in a timely fashion is often very difficult. Conventional microbiologic and histopathologic approaches generally are neither sensitive nor specific, and they often do not detect invasive fungal infection until late in the course of disease. Since early diagnosis may guide appropriate treatment and prevent mortality, there has been considerable interest in developing nonculture approaches to diagnosing fungal infections. These approaches include detection of specific host immune responses to fungal antigens, detection of specific macromolecular antigens using immunologic reagents, amplification and detection of specific fungal nucleic acid sequences, and detection and quantitation of specific fungal metabolite products. This work reviews the current status and recent developments as well as problems in the design of nonculture diagnostic methods for invasive fungal infections.

2018 ◽  
Vol 4 (3) ◽  
pp. 94 ◽  
Author(s):  
Nikolaos V. Sipsas ◽  
Maria N. Pagoni ◽  
Diamantis P. Kofteridis ◽  
Joseph Meletiadis ◽  
Georgia Vrioni ◽  
...  

There are concerns that the financial crisis in Greece negatively affected the management of invasive fungal infections (IFIs) among patients with hematological malignancies (HM). A working group (WG) was formed to explore the situation and make recommendations. A questionnaire was created and distributed to physicians caring for patients with HM, to gather information in a standardized manner on prescribing physicians, patient characteristics, availability of diagnostics, antifungal treatment practices and the conditions and particularities of Greek hospitals. A total of 141 physicians from 36 hematology units and laboratories located in 26 Greek hospitals participated. Regarding hospitalization conditions, only 56% reported that their patients were treated in isolated single or double bed rooms, 22% reported availability of HEPA filters, 47% reported construction works in progress, and an alarming 18% reported the presence of birds on open windows. Regarding diagnosis, only 31% reported availability of biomarkers for diagnosis of IFIs, 76% reported that CT scans were performed in a timely fashion, 42% reported prompt availability of broncho-alveolar lavage, and only 6% availability of therapeutic drug monitoring. Of concern, 26% of the responders reported non-availability of some antifungals. In conclusion, significant challenges exist for the optimal management of IFIs in patients with HM in Greece.


2014 ◽  
Vol 27 (3) ◽  
pp. 490-526 ◽  
Author(s):  
M. Arvanitis ◽  
T. Anagnostou ◽  
B. B. Fuchs ◽  
A. M. Caliendo ◽  
E. Mylonakis

2005 ◽  
Vol 11 (6) ◽  
pp. 278-287 ◽  
Author(s):  
Naoki Aikawa ◽  
Shigeru Kohno ◽  
Kazutoshi Shibuya ◽  
Yoshio Takesue ◽  
Shigefumi Maesaki ◽  
...  

Hematology ◽  
2003 ◽  
Vol 2003 (1) ◽  
pp. 438-472 ◽  
Author(s):  
Susan N. O’Brien ◽  
Nicole M.A. Blijlevens ◽  
Tahsine H. Mahfouz ◽  
Elias J. Anaissie

Abstract One of the most common complications involved in treating patients with hematologic cancer is infection. In many cases there are multiple factors that predispose these patients to infections such as neutropenia induced by therapy or bone marrow involvement, hypogammaglobulinemia, T-cell dysfunction, and mucosal damage. In addition, newer therapies have changed the spectrum of infection that is seen in these patients. In Section I, Dr. Blijlevens discusses mucosal damage as a major risk factor for complications of cytotoxic chemotherapy. She focuses on mucosal barrier injury (MBI) as manifest in the GI tract and will describe a pathological model to explain MBI, evaluate risk factors for development of this syndrome, explain the relationship between MBI and infection, and discuss treatment and prevention of this injury. Invasive fungal infections continue to represent a significant problem in patients with hematologic cancer. In Section II, Drs. Anaissie and Mahfouz review the latest developments in the diagnosis, prevention, and management of invasive fungal infections with a focus on a risk-adjusted approach to this problem. Finally, in Section III, Dr. O’Brien reviews infections associated with newer therapeutic regimens in hematologic cancers. The spectrum of infections has changed with the use of purine analogs and the advent of monoclonal antibodies. The profound T-cell suppression associated with these therapies has led to the emergence of previously rare infections such as cytomegalovirus. An approach to both prophylaxis and management of these infections is discussed.


Sign in / Sign up

Export Citation Format

Share Document